90 Seconds With… Paul Rennie from Neuroscientific biopharmaceuticals (ASX:NSB)
Got 90 seconds? Then listen to Chairman, Paul Rennie tell us about their company news.
Neuroscientific biopharmaceuticals (ASX:NSB) is an Australian biotechnology company developing novel disease modifying therapies for neurodegenerative disease such as Alzheimer’s, Multiple Sclerosis as well as ophthalmology indications caused by degeneration of the optic nerve.
Neuroscientific is currently finishing an IND enabling preclinical safety and toxicology program with its US partners and will be initiating first in human clinical studies later this year.
We gave Paul Rennie, Chairman of Neuroscientific, 90 seconds to tell us more about the recent announcement.
Have a good idea for our next 90 Seconds With segment? Email us at [email protected]
Related Topics

UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.